MedPath

Carmot Therapeutics, Inc.

Carmot Therapeutics, Inc. logo
🇺🇸United States
Ownership
Subsidiary
Established
2008-01-01
Employees
57
Market Cap
-
Website
http://carmot.us

Clinical Trials

7

Active:1
Completed:4

Trial Phases

2 Phases

Phase 1:3
Phase 2:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials

Phase 2
4 (57.1%)
Phase 1
3 (42.9%)

A Study of CT-388 in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

Phase 2
Recruiting
Conditions
Overweight or Obese
Type 2 Diabetes Mellitus (T2DM)
Interventions
Drug: Placebo
First Posted Date
2024-10-08
Last Posted Date
2025-09-16
Lead Sponsor
Carmot Therapeutics, Inc.
Target Recruit Count
360
Registration Number
NCT06628362
Locations
🇺🇸

Ark Clinical-Fountain Valley, Fountain Valley, California, United States

🇺🇸

Pinnacle Research Group, Llc; Central, Anniston, Alabama, United States

🇺🇸

Central Alabama Research, Birmingham, Alabama, United States

and more 82 locations

A Study of CT-388 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

Phase 2
Active, not recruiting
Conditions
Obesity
Overweight
Interventions
Drug: Placebo
First Posted Date
2024-07-29
Last Posted Date
2025-09-11
Lead Sponsor
Carmot Therapeutics, Inc.
Target Recruit Count
450
Registration Number
NCT06525935
Locations
🇺🇸

Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States

🇺🇸

Central Alabama Research, Homewood, Alabama, United States

🇺🇸

The Institute for Liver Health II LLC dba Arizona Clinical Trials; Arizona Liver Health, Mesa, Arizona, United States

and more 31 locations

A Study of CT-868 in Type 1 Diabetes Mellitus

Phase 2
Completed
Conditions
Obese
Type 1 Diabetes Mellitus
Overweight
Interventions
Device: CT-868 Pen Injector
Drug: CT-868 Pen Injector, Placebo
First Posted Date
2023-10-02
Last Posted Date
2025-07-17
Lead Sponsor
Carmot Therapeutics, Inc.
Target Recruit Count
111
Registration Number
NCT06062069
Locations
🇺🇸

John Muir Physician Network Clinical Research Center, Concord, California, United States

🇺🇸

Headlands Research- AMCR, Escondido, California, United States

🇺🇸

University of Colorado - Barbara Davis Center for Diabetes, Aurora, Colorado, United States

and more 19 locations

A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

Phase 1
Completed
Conditions
Type 1 Diabetes
Interventions
First Posted Date
2023-04-03
Last Posted Date
2024-12-27
Lead Sponsor
Carmot Therapeutics, Inc.
Target Recruit Count
32
Registration Number
NCT05794581
Locations
🇺🇸

Carmot Clinical Research Unit 101, Chula Vista, California, United States

A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

Phase 2
Conditions
Obesity
Type2 Diabetes
Interventions
Drug: Placebo
First Posted Date
2021-11-08
Last Posted Date
2022-07-26
Lead Sponsor
Carmot Therapeutics, Inc.
Target Recruit Count
96
Registration Number
NCT05110846
Locations
🇺🇸

Carmot Clinical Center US01, Los Angeles, California, United States

🇲🇽

Carmot Clinical Center MX04, Guadalajara, Jalisco, Mexico

🇲🇽

Carmot Clinical Center MX01, Monterrey, Nuevo Leon, Mexico

and more 3 locations
  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.